Abstract 2154
Background
The development of effective anti-emetic treatments has contributed to the resolution of emesis in chemotherapy patients (pts). Current research has focused on vomiting as the primary problem of chemotherapy-induced nausea and vomiting (CINV). The incidence and impact of nausea, particularly in cancer pts undergoing chemotherapy is under-reported and remains a major unmet medical need.
Methods
The study focused on nausea in pts undergoing chemotherapy. The primary endpoint was no nausea during the 120-hours overall phase after the first 3 consecutive cycles of treatment. Secondary endpoints included no nausea during day-7 and day-10 of cycle 1. This prospective, observational single centre study enrolled 95 pts undergoing intravenous chemotherapy, receiving guideline consistent CINV prophylaxis. There were LEC = 25 pts, MEC = 24 pts and HEC (included cisplatin and doxorubicin/cyclophosphamide-based chemotherapy) = 46 pts. Patient diaries were used to collect data from day-1 to day-5, day-7 and day-10 beginning with cycle-1 for up to 3 cycles. Nausea was reported by the pts using a visual analog scale (VAS). Vomiting episodes were recorded in the patient’s diaries and data was analysed as a secondary end-point.
Results
The incidence of nausea of the entire population was significantly higher than vomiting for cycle 1 (58% vs 14%; Chi2 22.271 p < 0.0000); for cycle 2 (51% vs 14%; Chi2 26.964 p < 0.0000) and for cycle 3 (46% vs 18%; Chi2 14.161 p < 0.0002). Nausea was continuous in 25% of the patients in all 3 cycles. For patients with documented intermittent nausea, the mean duration was 3.8 hours. The median maximum intensity of nausea was 6 (range 1-10) for all three cycles. The median time to development of first episode of nausea was 29 hours (range 1 to 90). Significant variables predicted for nausea in cycle 1 included, age (OR 0.177, p < 0.035) and history of morning sickness (OR 5.038, p < 0.032).
Conclusions
Despite the usage of guidelines consistent antiemetic prophylaxis, chemotherapy induced nausea remains a major unmet medical need in cancer pts. Further research should focus on treatment of nausea and patient’s risk factors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5751 - Phase 3 ALTA-3 study of brigatinib (BRG) vs alectinib (ALC) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)−positive non–small cell lung cancer (NSCLC) that progressed on crizotinib (CRZ)
Presenter: Sanjay Popat
Session: Poster Display session 1
Resources:
Abstract
5103 - CANOPY phase 3 program: Three studies evaluating canakinumab in patients with non-small cell lung cancer (NSCLC)
Presenter: Luis Paz-Ares
Session: Poster Display session 1
Resources:
Abstract
3666 - The Elderly Patient Individualized Chemotherapy (EPIC) trial, a study for an aged population of non-small cell lung cancer.
Presenter: Francesco Passiglia
Session: Poster Display session 1
Resources:
Abstract
4799 - KEYNOTE-495/KeyImPaCT: A Randomized, Biomarker-Directed, Phase 2 Trial of Pembrolizumab-Based Therapy for Non–Small Cell Lung Cancer (NSCLC)
Presenter: Martin Gutierrez
Session: Poster Display session 1
Resources:
Abstract
6035 - Safety, tolerability and activity of autologous T cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non small cell lung cancer: A Phase 1b/2a randomised pilot study
Presenter: Karen Reckamp
Session: Poster Display session 1
Resources:
Abstract
2176 - IFCT-1701 DICIPLE: a randomized phase 3 trial comparing continuation Nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in patients with PDL1-positive stage IV Non-Small Cell Lung Cancer (NSCLC) after Nivolumab-Ipilimumab induction treatment
Presenter: Gerard Zalcman
Session: Poster Display session 1
Resources:
Abstract
2352 - ATALANTE-1 randomized phase 3 trial, OSE-2101 versus standard treatment as second or third line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients
Presenter: Enriqueta Felip
Session: Poster Display session 1
Resources:
Abstract
2451 - Phase Ib dose-escalation/expansion study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumours
Presenter: Nicolas Girard
Session: Poster Display session 1
Resources:
Abstract
4285 - Radiosurgery followed by Tumor Treating Fields (TTFields) for brain metastases (1-10) from NSCLC in the phase 3 METIS trial
Presenter: Minesh Mehta
Session: Poster Display session 1
Resources:
Abstract
4909 - Nivolumab plus ipilimumab (NI) versus chemotherapy plus nivolumab (CN) in squamous cell lung cancer (SqCLC): the SQUINT trial
Presenter: Lorenza Landi
Session: Poster Display session 1
Resources:
Abstract